Biodistribution and Dosimetry Evaluation of [124I]FIAU

Exclusion Criteria

• •1. Unable to comply with study requirements
• •2. Indication in the opinion of the principal investigator for surgery within 48 hours of presentation.
• •3. Receipt of any antibiotic therapy in the 2 weeks preceding imaging
• •4. Immunosuppression, e.g., human immunodeficiency virus (HIV) infection, s/p organ transplantation, receipt of steroids for \> 10 days at \> 10 mg of prednisone equivalent daily within the 90 days prior to enrollment
• •5. Requirement for any medication that predisposes to lactic acidosis (e.g., metformin, iron, isoniazid and salicylates; see Appendix A)
• •6. Requirement for any medication that has potential mitochondrial toxicity, e.g., nucleoside analogues (zidovudine, didanosine, stavudine)
• •7. History of an inherited mitochondrial disorder (e.g., Leber's hereditary neuropathy, neuropathy, ataxia, retinitis pigmentosa and ptosis \[NARP\], myoneurogenic gastrointestinal encephalopathy \[MNGIE\], myoclonic epilepsy with ragged red fibers \[MERFF\] and mitochondrial myopathy, encephalomyopathy, lactic acidosis and stroke-like syndrome \[MELAS\]
• •8. Chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infection
• •9. Pre-existing myopathy or neuropathy
• •10. Abnormal liver function tests defined as alanine aminotransferase (ALT) \> the upper limit of normal (ULN), aspartate aminotransferase (AST) \> ULN, gamma glutamyl transferase (GGT) \> ULN
• •11. Alcohol use \> 3 units per day in men or 2 units per day in women or active intravenous drug use
• •12. Creatinine clearance \< 30 mL/min
• •13. Body mass index \> 40
• •14. Life expectancy \< 6 months
• •15. Hypersensitivity to iodine